About
Technology
Issues
FAQ
Links
Official Page
Pasotuxizumab, a BiTE
®
immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.